-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Sees Significant Decrease in Short Interest
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Sees Significant Decrease in Short Interest
Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 111,700 shares, a decline of 5.7% from the December 15th total of 118,500 shares. Based on an average daily trading volume, of 1,640,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.4% of the shares of the company are short sold.
Dermata Therapeutics Stock Up 15.0 %
Shares of DRMA opened at $0.29 on Monday. Dermata Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.45. The business has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.56.
Get Dermata Therapeutics alerts:Dermata Therapeutics (NASDAQ:DRMA – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, analysts expect that Dermata Therapeutics will post -0.82 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have commented on DRMA shares. Brookline Capital Management reiterated a "buy" rating on shares of Dermata Therapeutics in a research report on Monday, October 3rd. Maxim Group reduced their price objective on shares of Dermata Therapeutics from $4.00 to $1.00 in a research note on Tuesday, December 6th.Institutional Trading of Dermata Therapeutics
A hedge fund recently bought a new stake in Dermata Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 70,808 shares of the company's stock, valued at approximately $37,000. Virtu Financial LLC owned 0.70% of Dermata Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 1.63% of the stock is owned by hedge funds and other institutional investors.
About Dermata Therapeutics
(Get Rating)
Dermata Therapeutics, Inc, a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
See Also
- Get a free copy of the StockNews.com research report on Dermata Therapeutics (DRMA)
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 111,700 shares, a decline of 5.7% from the December 15th total of 118,500 shares. Based on an average daily trading volume, of 1,640,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.4% of the shares of the company are short sold.
皮膚治療, 公司. (NASDAQ: DRMA — 獲取評級) 是在十二月份短期利益大幅下降的接收者.截至十二月三十日,短期利息總額為 111,700 股,較十二月十五日共 118,500 股股份下降 5.7%。根據每日平均交易量 1,640,000 股,日數佔覆蓋率目前為 0.1 天。約 1.4% 的公司股份賣空。
Dermata Therapeutics Stock Up 15.0 %
皮膚療法股票上漲 15.0%
Shares of DRMA opened at $0.29 on Monday. Dermata Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.45. The business has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.56.
德瑞瑪股份在星期一以 0.29 美元開盤。皮膚治療有一個 12 個月低點 0.16 美元和 12 個月高點的 2.45 美元。該公司擁有 50 天的簡單移動平均線 0.37 美元和 200 天的簡單移動平均線 0.56 美元。
Dermata Therapeutics (NASDAQ:DRMA – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, analysts expect that Dermata Therapeutics will post -0.82 EPS for the current fiscal year.
皮膚治療(NASDAQ:DRMA-獲取評級)上週四宣布了其季度收益業績,週四,11 月 10 日。該公司報告了該季度的每股盈利(0.20 美元)。作為一個小組,分析師預計,真皮治療學將在當前財政年度發布 -0.82 每股收益。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
Institutional Trading of Dermata Therapeutics
真皮療法的機構交易
A hedge fund recently bought a new stake in Dermata Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 70,808 shares of the company's stock, valued at approximately $37,000. Virtu Financial LLC owned 0.70% of Dermata Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 1.63% of the stock is owned by hedge funds and other institutional investors.
一家對沖基金最近買入了 Dermata 治療股票的新股份。根據該公司最近向美國證券交易委員會(SEC)提交的 13F 表格中,Virtu 金融有限責任公司在第三季度收購了德瑪塔治療藥物公司(NASDAQ:DRMA-獲得評級)的新股份。該公司收購了該公司股票 70,808 股,價值約 37,000 美元。在最近向美國證券交易委員會(SEC)提交的文件中,Virtu Financial LLC 擁有 0.70% 的 Dermata 治療學。1.63% 的股票由對沖基金和其他機構投資者擁有。
About Dermata Therapeutics
關於皮膚治療
(Get Rating)
(取得評分)
Dermata Therapeutics, Inc, a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
Dermata Therapeutics, Inc 是一家臨床階段的生物技術公司,致力於識別,開發和商業化用於治療醫學和美容皮膚狀況的候選藥品候選人。該公司的主要候選產品為 DMT310,該產品已完成治療中度至重度痤瘡的 IIB 期臨床試驗;以及輕度至中度牛皮癬的 Ib 期概念驗證(POC)試驗,以及正在進行中度至嚴重度酒渣鼻治療的 2 期臨床試驗。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Dermata Therapeutics (DRMA)
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
- 獲取有關皮膚療法研究報告的免費副本
- C3.ai 股票是聊天室人工智能遊戲嗎?
- NVIDIA 展望改善:2023 年監視列表候選人
- 您應該在 2023 年購買哪種無線股票?
- 維珍銀河股票是否準備升降?
- 雪佛龍很可能在盈利前增加股息
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收真皮療法的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Dermata 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧